Andrew R Clamp

6PUBLICATIONS
71CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursQuery processing and optimisation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.

Robert D Morgan, Xin Wang, Bethany M Barnes

|May 09, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.

Alexander D Murphy, Catharine Porter, Ann White

|Aug 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.

Rachel N Grisham, Ignace Vergote, Susana Banerjee

|Apr 18, 2023
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.

Robert D Morgan, Andrew R Clamp, Bethany M Barnes

|Feb 17, 2023
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.

Robert D Morgan, Andrew R Clamp, Daniel J White

|Sep 18, 2020
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial.

Elizabeth C James, David Dunn, Adrian D Cook

Pageof 1

Frequent Collaborators

4 joint publications

Gordon C Jayson

4 joint publications

Robert D Morgan

3 joint publications

D Gareth R Evans

2 joint publications

Susana Banerjee